• TCAIM Regulates Mitochondrial Metabolism via OGDH Degradatio

  2026-07-20

  This study uncovers a novel mitochondrial regulatory mechanism, showing that the DNAJC co-chaperone TCAIM specifically binds and reduces a-ketoglutarate dehydrogenase (OGDH) protein levels, thereby modulating mitochondrial metabolism. The findings provide new insights into post-translational enzyme regulation and its impact on cellular energetics, with implications for metabolic research and disease modeling.

• MK-1775 (Wee1 Kinase Inhibitor): Precision Tools for Functio

  2026-07-20

  Explore how MK-1775, a potent Wee1 kinase inhibitor, enables precision targeting of cell cycle checkpoints in p53-deficient cancer models. This article offers a deeper, assay-focused perspective on functional biomarker discovery and robust protocol design.

• ZK53: Illuminating Mitochondrial ClpP Activation for Cancer

  2026-07-19

  Explore how ZK53, a selective human mitochondrial serine protease ClpP activator, enables unprecedented interrogation of mitochondrial dysfunction and metabolic rewiring in cancer. This article uniquely bridges core mechanistic pathways, advanced model design, and recent breakthroughs in translational regulation.

• Trichostatin A (TSA): Technical Guide for Epigenetic Studies

  2026-07-18

  Trichostatin A (TSA) is a benchmark histone deacetylase (HDAC) inhibitor used to dissect epigenetic regulation in mammalian cell models, especially for studying cell cycle arrest and breast cancer cell proliferation inhibition. It should be used when robust, well-characterized modulation of chromatin acetylation is required, with careful attention to solubility and stability parameters. TSA is not suitable for workflows requiring aqueous solubility or long-term stock solution storage.

• S63845 MCL1 Inhibitor: Precision Targeting of Apoptosis in C

  2026-07-17

  Explore how the S63845 MCL1 inhibitor enables precise activation of the mitochondrial apoptotic pathway in hematological cancer research. This article uniquely dissects combinatorial assay strategies, molecular mechanisms, and actionable protocol insights distinct from prior reviews.

• Baicalin Restores Adult Visual Plasticity in Amblyopia Model

  2026-07-17

  This study demonstrates that Baicalin, a flavone glycoside from Scutellaria baicalensis, reactivates ocular dominance plasticity and restores visual function in adult mice with amblyopia. The findings provide compelling evidence that pharmacological reopening of plasticity windows in the adult brain is achievable, offering a new direction for vision restoration research.

• T-5224 (C-Fos/AP-1 Inhibitor): Expanding Horizons in Inflamm

  2026-07-16

  Explore the multifaceted role of T-5224, a selective C-Fos/AP-1 inhibitor, in modulating inflammation and inducing ferroptosis. This article uniquely synthesizes mechanistic insights, protocol guidance, and translational potential for advanced disease models.

• Imipramine in Autophagy and Apoptosis Research: Protocols &

  2026-07-16

  Imipramine, a tricyclic antidepressant, is rapidly gaining traction as a multifaceted tool in autophagy, apoptosis, and tumor biology research. By bridging insights from lipidomics and ceramide-driven pathways, this article details practical workflows and troubleshooting strategies that empower advanced experimental designs using Imipramine from APExBIO.

• Inhibiting the CaN/FoxO1/FABP4 Axis to Prevent Foam Cell For

  2026-07-15

  This study elucidates how SERCA2 dysfunction in macrophages accelerates atherosclerosis by activating the calcineurin/FoxO1/FABP4 pathway, driving foam cell formation. Inhibiting this pathway—particularly targeting FABP4—restores lipid homeostasis and reduces lesion development, highlighting a promising therapeutic avenue for atherosclerosis research.

• Dual Terminal Oxidase Inhibition Enhances Bactericidal TB Re

  2026-07-15

  This study reveals that pretomanid, a bicyclic nitroimidazole derivative, exerts its potent bactericidal activity against Mycobacterium tuberculosis by simultaneously inhibiting both terminal oxidases of the respiratory chain. The results support rational combination regimens targeting terminal oxidases as a strategy to improve efficacy and suppress resistance in tuberculosis therapy.

• Neuroinflammatory CGRP/SP-Piezo2 Axis in Trigeminal Allodyni

  2026-07-14

  Liao et al. reveal that chronic trigeminal nerve root compression provokes a neuroinflammatory response driving mechanical allodynia through a Ca2+-dependent CGRP/SP-Piezo2 positive feedback loop. This work establishes new mechanistic links between ATP-driven signaling, Piezo2 upregulation, and pain sensitization, providing precise molecular targets for neuropathic pain and inflammation research.

• SHC-1 Inhibition Regulates CFTR Surface Abundance in Epithel

  2026-07-14

  This study characterizes how SHC-1 inhibition modulates plasma membrane CFTR channel abundance across different epithelial cell models. By dissecting the MAPK/SHC-1 signaling axis, the research clarifies both conserved and cell-specific mechanisms of CFTR internalization, advancing understanding relevant to cystic fibrosis and secretory epithelial diseases.

• α-Bungarotoxin: Decoding Cholinergic Blockade in Placental R

  2026-07-13

  Explore how α-Bungarotoxin enables precise nicotinic receptor blockade in models of cholinergic neurotransmission inhibition and placental necroptosis. This article uniquely bridges advanced receptor pharmacology with practical assay design, offering new insights for neuroscience and translational researchers.

• hiPSC-Derived Intestinal Organoids in CYP2C19 Substrate Stud

  2026-07-13

  This study presents a streamlined protocol for generating human pluripotent stem cell-derived intestinal organoids, advancing the physiological relevance and utility of in vitro pharmacokinetic studies. The model enables more accurate investigation of CYP2C19 substrate metabolism, addressing major limitations of traditional cell lines and animal models.

• SCH772984 HCl: Optimizing ERK1/2 Inhibitor Workflows in Canc

  2026-07-12

  SCH772984 HCl delivers precision ERK1/2 pathway inhibition, enabling advanced modeling of drug resistance and spatial translation control in cancer and cardiac research. Learn how to streamline experimental design, troubleshoot common pitfalls, and unlock new applications using this potent MAPK signaling pathway inhibitor.

455 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page